2005
DOI: 10.2169/internalmedicine.44.527
|View full text |Cite
|
Sign up to set email alerts
|

Autoantibodies to Aminoacyl-tRNA Synthetases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
23
0
1

Year Published

2011
2011
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 30 publications
(24 citation statements)
references
References 15 publications
(14 reference statements)
0
23
0
1
Order By: Relevance
“…The anti-non-Jo-1 subtypes refer to us as anti-PL-7, anti-PL-12, anti-OJ, anti-EJ, anti-KS, anti-Zo and anti-YRS or anti-Ha antibodies (Hirakata, 2005;Mimori et al, 2007;Solomon et al, 2011). Several characteristics of these anti-ARSs autoantibodies have been emphasized Hirakata, 2005;Solomon et al, 2011;Targoff, 2008):  they focus on functionally related protein enzymes (synthetases) implicated in normal vital cellular cycle, specifically targeting muscle and lung tissue;  they are highly selective, each autoantibody being directed to only one synthetase;  they are mutually exclusive in a given patient, with a few exception only a single antisynthetase being typically found;  they are generally associated with particular phenotypes, a characteristic clinical syndrome being known as "anti-synthetase syndrome", although distinct profiles are defined for each autoantibody; and  they are associated with particular genotypes. Even thought to represent only disease biomarkers, it seems that anti-synthetase autoantibodies are active players in the immunopathogenesis of polymyositis and dermatomyositis.…”
Section: Anti-aminoacyl-trna Synthetases Auto-antibodiesmentioning
confidence: 99%
See 3 more Smart Citations
“…The anti-non-Jo-1 subtypes refer to us as anti-PL-7, anti-PL-12, anti-OJ, anti-EJ, anti-KS, anti-Zo and anti-YRS or anti-Ha antibodies (Hirakata, 2005;Mimori et al, 2007;Solomon et al, 2011). Several characteristics of these anti-ARSs autoantibodies have been emphasized Hirakata, 2005;Solomon et al, 2011;Targoff, 2008):  they focus on functionally related protein enzymes (synthetases) implicated in normal vital cellular cycle, specifically targeting muscle and lung tissue;  they are highly selective, each autoantibody being directed to only one synthetase;  they are mutually exclusive in a given patient, with a few exception only a single antisynthetase being typically found;  they are generally associated with particular phenotypes, a characteristic clinical syndrome being known as "anti-synthetase syndrome", although distinct profiles are defined for each autoantibody; and  they are associated with particular genotypes. Even thought to represent only disease biomarkers, it seems that anti-synthetase autoantibodies are active players in the immunopathogenesis of polymyositis and dermatomyositis.…”
Section: Anti-aminoacyl-trna Synthetases Auto-antibodiesmentioning
confidence: 99%
“…Several fascinating paradigms have been effectively anticipated to explain why and how certain intracellular proteins, widely originating in all cellular types, are selectively and specifically targeted in IIMs ). Anti-ARS autoantibodies are associated with anti-synthetase syndrome (ASS), classically defined by several characteristic clinical features including myositis, interstitial lung disease (ILD), arthritis, fever, Raynaud's phenomenon and "mechanic's hands", in addition to other typical skin lesions such as Gottron's papules and heliotrope rash (Betteridge et al, 2007;Betteridge et al, 2009;Gunawardena et al, 2009;Hirakata, 2005). Moreover, distinct associations between certain anti-synthetases profile and corresponding clinical pattern have actually been up-dated.…”
Section: Anti-aminoacyl-trna Synthetases Auto-antibodiesmentioning
confidence: 99%
See 2 more Smart Citations
“…The autoantibodies directed against ARSs have been associated with a clinical picture, including myositis, arthritis, interstinal pneumonia, systemic lupus erythematosus, and other features that have been referred to as the ''anti-synthetase syndrome.'' (12) These diverse connections of ARSs with various human diseases make them attractive targets for the development of therapeutics, although as therapeutic agents of themselves, and as targets for drugs, tRNA synthetases will yield many opportunities for disease intervention. (13) Human tyrosyl-tRNA synthetase (TyrRS) is inactive as a cell-signaling molecule, but it can be split into two distinct cytokines under apoptotic conditions.…”
Section: Introductionmentioning
confidence: 99%